 Right. This is for early stage patients. And that's another difficulty with, I think, when these drugs are on the market and they're being used in real life is catching patients early in their disease and convincing them to start using the treatment. That's another challenge is that this is really just for early Alzheimer's patients. And what does that mean? Does that mean patients who don't yet have any symptoms? What is early stage?